

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2025/106751 A9

(43) International Publication Date
22 May 2025 (22.05.2025)

(51) International Patent Classification:

A61K 38/12 (2006.01) *A61P 3/00* (2006.01)
A61K 31/513 (2006.01) *A61P 3/04* (2006.01)
A61K 31/549 (2006.01) *A61K 38/08* (2019.01)

(21) International Application Number:

PCT/US2024/056024

(22) International Filing Date:

14 November 2024 (14.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/548,506 14 November 2023 (14.11.2023) US

(71) Applicant: **RHYTHM PHARMACEUTICALS, INC.**

[US/US]; 222 Berkeley Street, 12th Floor, Boston, MA
02116 (US).

(72) Inventors: **GRUJIC, Danica**; c/o Rhythm Pharmaceuticals,

Inc., 222 Berkeley Street, 12th Floor, Boston, MA
02116 (US). **MEEKER, David, Pell**; c/o Rhythm Pharmaceuticals,
Inc., 222 Berkeley Street, 12th Floor, Boston,
MA 02116 (US). **WIGERINCK, Piet**; c/o Rhythm Pharmaceuticals,
Inc., 222 Berkeley Street, 12th Floor, Boston,
MA 02116 (US). **VAN DER SANDE, Claudine**; c/o
Rhythm Pharmaceuticals, Inc., 222 Berkeley Street, 12th
Floor, Boston, MA 02116 (US). **GARFIELD, Alastair**; c/
o Rhythm Pharmaceuticals, Inc., 222 Berkeley Street, 12th
Floor, Boston, MA 02116 (US).

(74) Agent: **LARKIN, Angelyn**; Lando & Anastasi, LLP, 60

State Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(48) Date of publication of this corrected version:

10 July 2025 (10.07.2025)

(15) Information about Correction:

see Notice of 10 July 2025 (10.07.2025)

(54) Title: COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE

(57) Abstract: The disclosure relates to a method of treating a disease or disorder in a subject using a combination of: (i) a potassium channel activator (e.g., a SURx/Kirx channel activator compound) or a pharmaceutically acceptable salt thereof; and (ii) a melanocortin-4 receptor (MC4R) agonist.



WO 2025/106751 A9